世界のヒト遺伝子治療市場予測2022-2028:非ウイルスベクター、ウイルスベクター

【英語タイトル】Human Gene Therapy Market, Global Outlook and Forecast 2022-2028

Market Monitor Globalが出版した調査資料(MMG22NV12583)・商品コード:MMG22NV12583
・発行会社(調査会社):Market Monitor Global
・発行日:2022年11月
・ページ数:123
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野:製薬・ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,250 ⇒換算¥481,000見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD4,225 ⇒換算¥625,300見積依頼/購入/質問フォーム
Enterprise User(閲覧人数制限なし)USD4,875 ⇒換算¥721,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界のヒト遺伝子治療市場規模と予測を収録しています。・世界のヒト遺伝子治療市場:売上、2017年-2022年、2023年-2028年
・世界のヒト遺伝子治療市場:販売量、2017年-2022年、2023年-2028年
・世界のトップ5企業、2021年

世界のヒト遺伝子治療市場は2021年に000Mドルと評価され、予測期間中に000%のCAGRで2028年までに000Mドルに達すると予測されています。米国市場は2021年に000Mドルと推定されており、中国は2028年までに000Mドルに達すると予測されています。「非ウイルスベクター」セグメントは今後6年間、000%のCAGRで2028年までに000Mドルに成長すると予測されています。

ヒト遺伝子治療のグローバル主要企業は、Biogen、 Sarepta Therapeutics、 Gilead Sciences、 Amgen、 Novartis、 Orchard Therapeutics、 Spark Therapeutics、 Agc Biologics、 Anges、 Bluebird Bio、 Jazz Pharmaceuticals、 Dynavax Technologies、 Human Stem Cells Institute、 Sibiono Genetech、 Shanghai Sunway Biotech、 Uniqure N.V.、 Gensight Biologics S.A.、 Celgene Corporation、 Cellectisなどです。2021年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、ヒト遺伝子治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のヒト遺伝子治療市場:タイプ別、2017年-2022年、2023年-2028年
世界のヒト遺伝子治療市場:タイプ別市場シェア、2021年
・非ウイルスベクター、ウイルスベクター

世界のヒト遺伝子治療市場:用途別、2017年-2022年、2023年-2028年
世界のヒト遺伝子治療市場:用途別市場シェア、2021年
・神経疾患、がん、DMD(デュシェンヌ型筋ジストロフィー)、肝臓疾患、その他

世界のヒト遺伝子治療市場:地域・国別、2017年-2022年、2023年-2028年
世界のヒト遺伝子治療市場:地域別市場シェア、2021年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるヒト遺伝子治療のグローバル売上、2017年-2022年
・主要企業におけるヒト遺伝子治療のグローバル売上シェア、2021年
・主要企業におけるヒト遺伝子治療のグローバル販売量、2017年-2022年
・主要企業におけるヒト遺伝子治療のグローバル販売量シェア、2021年

さらに、当レポートは主要企業のプロファイルを提示します。
Biogen、 Sarepta Therapeutics、 Gilead Sciences、 Amgen、 Novartis、 Orchard Therapeutics、 Spark Therapeutics、 Agc Biologics、 Anges、 Bluebird Bio、 Jazz Pharmaceuticals、 Dynavax Technologies、 Human Stem Cells Institute、 Sibiono Genetech、 Shanghai Sunway Biotech、 Uniqure N.V.、 Gensight Biologics S.A.、 Celgene Corporation、 Cellectis

*************************************************************

・調査・分析レポートの概要
ヒト遺伝子治療市場の定義
市場セグメント
世界のヒト遺伝子治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のヒト遺伝子治療市場規模
世界のヒト遺伝子治療市場規模:2021年 VS 2028年
世界のヒト遺伝子治療市場規模と予測 2017年-2028年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのヒト遺伝子治療の売上
グローバルトップ3およびトップ5企業、2021年売上ベース
グローバル企業のヒト遺伝子治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:非ウイルスベクター、ウイルスベクター
ヒト遺伝子治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:神経疾患、がん、DMD(デュシェンヌ型筋ジストロフィー)、肝臓疾患、その他
ヒト遺伝子治療の用途別グローバル売上・予測

・地域別市場分析
地域別ヒト遺伝子治療市場規模 2021年と2028年
地域別ヒト遺伝子治療売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
Biogen、 Sarepta Therapeutics、 Gilead Sciences、 Amgen、 Novartis、 Orchard Therapeutics、 Spark Therapeutics、 Agc Biologics、 Anges、 Bluebird Bio、 Jazz Pharmaceuticals、 Dynavax Technologies、 Human Stem Cells Institute、 Sibiono Genetech、 Shanghai Sunway Biotech、 Uniqure N.V.、 Gensight Biologics S.A.、 Celgene Corporation、 Cellectis
...

Gene therapy is a medical approach that treats or prevents disease by correcting the underlying genetic problem. Gene therapy techniques allow doctors to treat a disorder by altering a person’s genetic makeup instead of using drugs or surgery.
This report contains market size and forecasts of Human Gene Therapy in global, including the following market information:
Global Human Gene Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Human Gene Therapy Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Human Gene Therapy companies in 2021 (%)
The global Human Gene Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Non-viral Vectors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Human Gene Therapy include Biogen, Sarepta Therapeutics, Gilead Sciences, Amgen, Novartis, Orchard Therapeutics, Spark Therapeutics, Agc Biologics and Anges, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Human Gene Therapy manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Gene Therapy Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Gene Therapy Market Segment Percentages, by Type, 2021 (%)
Non-viral Vectors
Viral Vectors
Global Human Gene Therapy Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Gene Therapy Market Segment Percentages, by Application, 2021 (%)
Neurological Diseases
Cancer
DMD (Duchenne Muscular Dystrophy)
Hepatological Diseases
Others
Global Human Gene Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Gene Therapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Gene Therapy revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Human Gene Therapy revenues share in global market, 2021 (%)
Key companies Human Gene Therapy sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Human Gene Therapy sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Biogen
Sarepta Therapeutics
Gilead Sciences
Amgen
Novartis
Orchard Therapeutics
Spark Therapeutics
Agc Biologics
Anges
Bluebird Bio
Jazz Pharmaceuticals
Dynavax Technologies
Human Stem Cells Institute
Sibiono Genetech
Shanghai Sunway Biotech
Uniqure N.V.
Gensight Biologics S.A.
Celgene Corporation
Cellectis
Sangamo Therapeutics
Mustang Bio
AGTC
Poseida Therapeutics

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Human Gene Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Human Gene Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Human Gene Therapy Overall Market Size
2.1 Global Human Gene Therapy Market Size: 2021 VS 2028
2.2 Global Human Gene Therapy Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Human Gene Therapy Sales: 2017-2028
3 Company Landscape
3.1 Top Human Gene Therapy Players in Global Market
3.2 Top Global Human Gene Therapy Companies Ranked by Revenue
3.3 Global Human Gene Therapy Revenue by Companies
3.4 Global Human Gene Therapy Sales by Companies
3.5 Global Human Gene Therapy Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Human Gene Therapy Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Human Gene Therapy Product Type
3.8 Tier 1, Tier 2 and Tier 3 Human Gene Therapy Players in Global Market
3.8.1 List of Global Tier 1 Human Gene Therapy Companies
3.8.2 List of Global Tier 2 and Tier 3 Human Gene Therapy Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Human Gene Therapy Market Size Markets, 2021 & 2028
4.1.2 Non-viral Vectors
4.1.3 Viral Vectors
4.2 By Type – Global Human Gene Therapy Revenue & Forecasts
4.2.1 By Type – Global Human Gene Therapy Revenue, 2017-2022
4.2.2 By Type – Global Human Gene Therapy Revenue, 2023-2028
4.2.3 By Type – Global Human Gene Therapy Revenue Market Share, 2017-2028
4.3 By Type – Global Human Gene Therapy Sales & Forecasts
4.3.1 By Type – Global Human Gene Therapy Sales, 2017-2022
4.3.2 By Type – Global Human Gene Therapy Sales, 2023-2028
4.3.3 By Type – Global Human Gene Therapy Sales Market Share, 2017-2028
4.4 By Type – Global Human Gene Therapy Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application – Global Human Gene Therapy Market Size, 2021 & 2028
5.1.2 Neurological Diseases
5.1.3 Cancer
5.1.4 DMD (Duchenne Muscular Dystrophy)
5.1.5 Hepatological Diseases
5.1.6 Others
5.2 By Application – Global Human Gene Therapy Revenue & Forecasts
5.2.1 By Application – Global Human Gene Therapy Revenue, 2017-2022
5.2.2 By Application – Global Human Gene Therapy Revenue, 2023-2028
5.2.3 By Application – Global Human Gene Therapy Revenue Market Share, 2017-2028
5.3 By Application – Global Human Gene Therapy Sales & Forecasts
5.3.1 By Application – Global Human Gene Therapy Sales, 2017-2022
5.3.2 By Application – Global Human Gene Therapy Sales, 2023-2028
5.3.3 By Application – Global Human Gene Therapy Sales Market Share, 2017-2028
5.4 By Application – Global Human Gene Therapy Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region – Global Human Gene Therapy Market Size, 2021 & 2028
6.2 By Region – Global Human Gene Therapy Revenue & Forecasts
6.2.1 By Region – Global Human Gene Therapy Revenue, 2017-2022
6.2.2 By Region – Global Human Gene Therapy Revenue, 2023-2028
6.2.3 By Region – Global Human Gene Therapy Revenue Market Share, 2017-2028
6.3 By Region – Global Human Gene Therapy Sales & Forecasts
6.3.1 By Region – Global Human Gene Therapy Sales, 2017-2022
6.3.2 By Region – Global Human Gene Therapy Sales, 2023-2028
6.3.3 By Region – Global Human Gene Therapy Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country – North America Human Gene Therapy Revenue, 2017-2028
6.4.2 By Country – North America Human Gene Therapy Sales, 2017-2028
6.4.3 US Human Gene Therapy Market Size, 2017-2028
6.4.4 Canada Human Gene Therapy Market Size, 2017-2028
6.4.5 Mexico Human Gene Therapy Market Size, 2017-2028
6.5 Europe
6.5.1 By Country – Europe Human Gene Therapy Revenue, 2017-2028
6.5.2 By Country – Europe Human Gene Therapy Sales, 2017-2028
6.5.3 Germany Human Gene Therapy Market Size, 2017-2028
6.5.4 France Human Gene Therapy Market Size, 2017-2028
6.5.5 U.K. Human Gene Therapy Market Size, 2017-2028
6.5.6 Italy Human Gene Therapy Market Size, 2017-2028
6.5.7 Russia Human Gene Therapy Market Size, 2017-2028
6.5.8 Nordic Countries Human Gene Therapy Market Size, 2017-2028
6.5.9 Benelux Human Gene Therapy Market Size, 2017-2028
6.6 Asia
6.6.1 By Region – Asia Human Gene Therapy Revenue, 2017-2028
6.6.2 By Region – Asia Human Gene Therapy Sales, 2017-2028
6.6.3 China Human Gene Therapy Market Size, 2017-2028
6.6.4 Japan Human Gene Therapy Market Size, 2017-2028
6.6.5 South Korea Human Gene Therapy Market Size, 2017-2028
6.6.6 Southeast Asia Human Gene Therapy Market Size, 2017-2028
6.6.7 India Human Gene Therapy Market Size, 2017-2028
6.7 South America
6.7.1 By Country – South America Human Gene Therapy Revenue, 2017-2028
6.7.2 By Country – South America Human Gene Therapy Sales, 2017-2028
6.7.3 Brazil Human Gene Therapy Market Size, 2017-2028
6.7.4 Argentina Human Gene Therapy Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Human Gene Therapy Revenue, 2017-2028
6.8.2 By Country – Middle East & Africa Human Gene Therapy Sales, 2017-2028
6.8.3 Turkey Human Gene Therapy Market Size, 2017-2028
6.8.4 Israel Human Gene Therapy Market Size, 2017-2028
6.8.5 Saudi Arabia Human Gene Therapy Market Size, 2017-2028
6.8.6 UAE Human Gene Therapy Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Biogen
7.1.1 Biogen Corporate Summary
7.1.2 Biogen Business Overview
7.1.3 Biogen Human Gene Therapy Major Product Offerings
7.1.4 Biogen Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.1.5 Biogen Key News
7.2 Sarepta Therapeutics
7.2.1 Sarepta Therapeutics Corporate Summary
7.2.2 Sarepta Therapeutics Business Overview
7.2.3 Sarepta Therapeutics Human Gene Therapy Major Product Offerings
7.2.4 Sarepta Therapeutics Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.2.5 Sarepta Therapeutics Key News
7.3 Gilead Sciences
7.3.1 Gilead Sciences Corporate Summary
7.3.2 Gilead Sciences Business Overview
7.3.3 Gilead Sciences Human Gene Therapy Major Product Offerings
7.3.4 Gilead Sciences Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.3.5 Gilead Sciences Key News
7.4 Amgen
7.4.1 Amgen Corporate Summary
7.4.2 Amgen Business Overview
7.4.3 Amgen Human Gene Therapy Major Product Offerings
7.4.4 Amgen Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.4.5 Amgen Key News
7.5 Novartis
7.5.1 Novartis Corporate Summary
7.5.2 Novartis Business Overview
7.5.3 Novartis Human Gene Therapy Major Product Offerings
7.5.4 Novartis Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.5.5 Novartis Key News
7.6 Orchard Therapeutics
7.6.1 Orchard Therapeutics Corporate Summary
7.6.2 Orchard Therapeutics Business Overview
7.6.3 Orchard Therapeutics Human Gene Therapy Major Product Offerings
7.6.4 Orchard Therapeutics Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.6.5 Orchard Therapeutics Key News
7.7 Spark Therapeutics
7.7.1 Spark Therapeutics Corporate Summary
7.7.2 Spark Therapeutics Business Overview
7.7.3 Spark Therapeutics Human Gene Therapy Major Product Offerings
7.7.4 Spark Therapeutics Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.7.5 Spark Therapeutics Key News
7.8 Agc Biologics
7.8.1 Agc Biologics Corporate Summary
7.8.2 Agc Biologics Business Overview
7.8.3 Agc Biologics Human Gene Therapy Major Product Offerings
7.8.4 Agc Biologics Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.8.5 Agc Biologics Key News
7.9 Anges
7.9.1 Anges Corporate Summary
7.9.2 Anges Business Overview
7.9.3 Anges Human Gene Therapy Major Product Offerings
7.9.4 Anges Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.9.5 Anges Key News
7.10 Bluebird Bio
7.10.1 Bluebird Bio Corporate Summary
7.10.2 Bluebird Bio Business Overview
7.10.3 Bluebird Bio Human Gene Therapy Major Product Offerings
7.10.4 Bluebird Bio Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.10.5 Bluebird Bio Key News
7.11 Jazz Pharmaceuticals
7.11.1 Jazz Pharmaceuticals Corporate Summary
7.11.2 Jazz Pharmaceuticals Human Gene Therapy Business Overview
7.11.3 Jazz Pharmaceuticals Human Gene Therapy Major Product Offerings
7.11.4 Jazz Pharmaceuticals Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.11.5 Jazz Pharmaceuticals Key News
7.12 Dynavax Technologies
7.12.1 Dynavax Technologies Corporate Summary
7.12.2 Dynavax Technologies Human Gene Therapy Business Overview
7.12.3 Dynavax Technologies Human Gene Therapy Major Product Offerings
7.12.4 Dynavax Technologies Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.12.5 Dynavax Technologies Key News
7.13 Human Stem Cells Institute
7.13.1 Human Stem Cells Institute Corporate Summary
7.13.2 Human Stem Cells Institute Human Gene Therapy Business Overview
7.13.3 Human Stem Cells Institute Human Gene Therapy Major Product Offerings
7.13.4 Human Stem Cells Institute Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.13.5 Human Stem Cells Institute Key News
7.14 Sibiono Genetech
7.14.1 Sibiono Genetech Corporate Summary
7.14.2 Sibiono Genetech Business Overview
7.14.3 Sibiono Genetech Human Gene Therapy Major Product Offerings
7.14.4 Sibiono Genetech Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.14.5 Sibiono Genetech Key News
7.15 Shanghai Sunway Biotech
7.15.1 Shanghai Sunway Biotech Corporate Summary
7.15.2 Shanghai Sunway Biotech Business Overview
7.15.3 Shanghai Sunway Biotech Human Gene Therapy Major Product Offerings
7.15.4 Shanghai Sunway Biotech Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.15.5 Shanghai Sunway Biotech Key News
7.16 Uniqure N.V.
7.16.1 Uniqure N.V. Corporate Summary
7.16.2 Uniqure N.V. Business Overview
7.16.3 Uniqure N.V. Human Gene Therapy Major Product Offerings
7.16.4 Uniqure N.V. Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.16.5 Uniqure N.V. Key News
7.17 Gensight Biologics S.A.
7.17.1 Gensight Biologics S.A. Corporate Summary
7.17.2 Gensight Biologics S.A. Business Overview
7.17.3 Gensight Biologics S.A. Human Gene Therapy Major Product Offerings
7.17.4 Gensight Biologics S.A. Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.17.5 Gensight Biologics S.A. Key News
7.18 Celgene Corporation
7.18.1 Celgene Corporation Corporate Summary
7.18.2 Celgene Corporation Business Overview
7.18.3 Celgene Corporation Human Gene Therapy Major Product Offerings
7.18.4 Celgene Corporation Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.18.5 Celgene Corporation Key News
7.19 Cellectis
7.19.1 Cellectis Corporate Summary
7.19.2 Cellectis Business Overview
7.19.3 Cellectis Human Gene Therapy Major Product Offerings
7.19.4 Cellectis Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.19.5 Cellectis Key News
7.20 Sangamo Therapeutics
7.20.1 Sangamo Therapeutics Corporate Summary
7.20.2 Sangamo Therapeutics Business Overview
7.20.3 Sangamo Therapeutics Human Gene Therapy Major Product Offerings
7.20.4 Sangamo Therapeutics Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.20.5 Sangamo Therapeutics Key News
7.21 Mustang Bio
7.21.1 Mustang Bio Corporate Summary
7.21.2 Mustang Bio Business Overview
7.21.3 Mustang Bio Human Gene Therapy Major Product Offerings
7.21.4 Mustang Bio Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.21.5 Mustang Bio Key News
7.22 AGTC
7.22.1 AGTC Corporate Summary
7.22.2 AGTC Business Overview
7.22.3 AGTC Human Gene Therapy Major Product Offerings
7.22.4 AGTC Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.22.5 AGTC Key News
7.23 Poseida Therapeutics
7.23.1 Poseida Therapeutics Corporate Summary
7.23.2 Poseida Therapeutics Business Overview
7.23.3 Poseida Therapeutics Human Gene Therapy Major Product Offerings
7.23.4 Poseida Therapeutics Human Gene Therapy Sales and Revenue in Global (2017-2022)
7.23.5 Poseida Therapeutics Key News
8 Global Human Gene Therapy Production Capacity, Analysis
8.1 Global Human Gene Therapy Production Capacity, 2017-2028
8.2 Human Gene Therapy Production Capacity of Key Manufacturers in Global Market
8.3 Global Human Gene Therapy Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Human Gene Therapy Supply Chain Analysis
10.1 Human Gene Therapy Industry Value Chain
10.2 Human Gene Therapy Upstream Market
10.3 Human Gene Therapy Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Human Gene Therapy Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



★調査レポート[世界のヒト遺伝子治療市場予測2022-2028:非ウイルスベクター、ウイルスベクター] (コード:MMG22NV12583)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のヒト遺伝子治療市場予測2022-2028:非ウイルスベクター、ウイルスベクター]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆